Dr. Saganuwan Alhaji Saganuwan, Department of Veterinary Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, University of Agriculture, P.M.B. 2373, Makurdi, Benue State, Nigeria.

Abstract
Parkinsonism is a neuro-degenerative disease caused by destruction or impairment of basal ganglia which secretes dopamine from dopaminergic nerve that is connected to cholinergic nerve that secretes acetylcholine leading to decreased level of dopamine production. Piroxicam when administered to monogastric animals caused Parkinson-like effects characterize by opistothonus, torticollis, hypotention and sedation which are extrapyramidal. Therefore piroxicam may cause damage to basal ganglia resulting cholinergic effect. However, hydroxylated and carboxybenzothiazine metabolites of piroxicam must have been responsible for dopaminergic effect similar to that of fluphenazine in dose-dependent fashion.

Keywords
Piroxicam, parkinsonism, acetylcholine, dopamine, basal ganglia

Cite this paper
Dr. Saganuwan Alhaji Saganuwan, PIROXICAM MAY CAUSE PARKINSONISM IN HUMANS: A MINI REVIEW , SCIREA Journal of Health. Volume 3, Issue 3, June 2019 | PP. 62-69.

References

[ 1 ]	Tripathi KD. Essentials of Medical Pharmacology, 7th ed., Jaypee Brothers Medical Publishers, New Delhi, 2003; p 1002.
[ 2 ]	Bhattacharya P, Pandey AK, Paul S, et al. Aquaporin – 4 inhibition mediates piroxicam-induced neuro-protection against focal cerebral ischaemia/perfusion injury in rodents. Plus One 2013; 8(9): 1 – 13.
[ 3 ]	Eliasson MJL, Sampei K, Mandir AS, et al. Poly (ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischaemia. Nat Med 1997; 3(10): 1089 – 1095.
[ 4 ]	Saganuwan SA, Orinya OA. Toxico-neurological effects of piroxicam in monogastric animals. J. Exper. Neurosc. 2016; 10:121 – 120.
[ 5 ]	Ballington DA, Laughinlin MM. Pharmacology, 5th ed., Med Tec, Scientific International, Pvt. Ltd., New Delhi, India, 2014; p. 916.
[ 6 ]	Kapoor AK, Raju SM. Illustrated Medical Pharmacology, Jaypee Brothers Medical Publishers (p) Ltd., New Delhi, India, 2013; p. 874.
[ 7 ]	Stegman JK. Stedman’s Medical Dictionary, 28th ed., Lippincott Williams & Wilkins, A Wolters Kluwer Company, Baltimore, USA, 2006; p. 2169.
[ 8 ]	Danesh HB. The Psychology of Spirituality from Divided Self to Integrated self, Sterling Publishers Private Ltd., New Delhi, India, 2006; p. 270.
[ 9 ]	Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol 2012; 8(1); 15 – 21.
[ 10 ]	Hall RA, Jackson RB, Swain JM. Neurotoxic reaction resulting from chlorpromazine administration. JAMA, 1956; 161: 214 – 218.
[ 11 ]	Barbosa MT, Caramelli P, Maia DP, C. at al. Parkinsonism and parkinson’s disease in the elderly: a community based survey in Brazil (the Bambui study) Mov. Disorder 2006; 21: 800 – 808.
[ 12 ]	Jang H, Boltz DA, Webster RG, et al. Viral parkinsonism. Biochem Biophy Act 2000; 1792: 714 – 721.
[ 13 ]	Molho ES, Factor SA. Secondary causes of parkinsonism. In: Parkinson’s Disease and Movement Disorders, Human Press, 2000; p. 211 – 228.
[ 14 ]	Susman E. Chemo-induced parkinsonism controlled with levodopa. Oncol Time 2001; 23(12): 59.
[ 15 ]	Tanner CM. Occupational and environmental causes of parkinsonism. Occup Med 1991; 7(3): 503 – 513.
[ 16 ]	Javitch JA, Amato RJD, Strittmatter SM, et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985; 2173 – 2177.
[ 17 ]	Grosset KA, Grosset DG. Prescribed drugs and neurological complications. J Neurol Neurosurg Psych 2004; 75:3.
[ 18 ]	Kwakye G, Paoliello MMB, Mukhopadhyay S, et al. Manganese-induced parkinsonism and parkinson’s disease: shared and distinguishable features. Int J Environ Res Public Healt 2015; 12:7519 – 7540.
[ 19 ]	Gulin O. Magnetic Resonance Spectroscopy of Degenerative Brain Diseases, Springer, London 2016; p. 268.
[ 20 ]	Frank C, Pari G, Rossiter JP. Approach to diagnosis of Parkinson disease. Canad Family Physic 2006; 52: 862 – 868.
[ 21 ]	Granado N, Ares-Santos S, Moratalla R. Methamphetamine and parkinsom’s disease. Parkinson’s Dis 2013; ID308052:10
[ 22 ]	Vale TC, Barbosa MT, Caramelli P, et al. Vascular parkinsonism and cognitive impairment. Damat. Neuropsychol. 2012; 6(3): 137 – 144.
[ 23 ]	Saganuwan SA. Physicochemical and structure-activity properties of piroxicam – a mini review. Comparat Clin Pathol 2016; 25(5): 941 – 945.
[ 24 ]	Saganuwan SA. In vivo piroxicam metabolites: possible source for synthesis of central nervous system acting drugs. Centr Nerv Syst Agent Med Chem 2017; 17(1): 1 – 6.
[ 25 ]	Newman AH, Beuming T, Banala AK, et al. Molecular determinants of selectivity and efficacy at the dopamine D3 receptor. J Med Chem 2012; 55(5): 6689 – 6699.
[ 26 ]	Saganuwan SA. In vivo piroxicam metabolites. Possible source for synthesis of central nervous system (CNS) acting depressants. Centr Nerv Syst Agent Med Chem 2017; 1:1 – 6.
[ 27 ]	Siddiqui WA. Synthesis of piroxicam-related heterocyclic molecules and evaluation of their biological activities. Ph.D. Thesis. Government College University, Cahore, Pakistan, 2007.
[ 28 ]	Thomae K. Pharmacology of indoxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibitor of COX2. Br. J. Rheumatol. 1966; 35(1): 4 – 12.
[ 29 ]	Teema AM, Zaitone SA, Moustafa YM. Ibuprofen or piroxicam protects nigral neurons and delays the development of L-dopa induced dyskinesia in rats with experimental parkinsonism: Influence on angiogenesis. Neuropharmacol 2016; 107: 432 – 451.
[ 30 ]	Saganuwan SA. Fluphenazine (a typical antipsychotic) has a purgative effect on turkey. J Neurosci 2015, 50(3): 112 – 122.
[ 31 ]	Saganuwan SA. Therapeutic causes of Stevens-Johnson syndrome-a min review. Ope Access J toxicol 2018;1(2):1-4.